Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTQ13FT)

• DTT Name: T-cell-specific surface glycoprotein CD28 (CD28) DTT Info
• Gene Name: CD28

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Belatacept	DMXLYQF	Kidney transplant rejection	NE84	Approved	[1]

11 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AB-103	DMPDQ8T	Necrotizing soft tissue infection	1B71	Phase 3	[2]
Lulizumab pegol	DMGWZ93	Systemic lupus erythematosus	4A40.0	Phase 2	[3]
AU101	DMLAKPI	Osteosarcoma	2B51	Phase 1/2	[4]
REGN5668	DMH1UV5	Ovarian cancer	2C73	Phase 1/2	[5]
REGN5678	DM0Y6WU	Prostate cancer	2C82.0	Phase 1/2	[6]
CD19-CAR and CD28-CAR T Cells	DMUR1MN	Acute lymphoblastic leukaemia	2A85	Phase 1	[7]
CD28 and CD137 CAR-T Cells	DMFGQXB	Acute lymphoblastic leukaemia	2A85	Phase 1	[8]
RG6333	DM1BRF2	Non-hodgkin lymphoma	2B33.5	Phase 1	[9]
RO7443904	DMSWZNU	Non-hodgkin lymphoma	2B33.5	Phase 1	[10]
SAR442257	DMXD5QP	Malignant neoplasm	2A00-2F9Z	Phase 1	[11]
SAR443216	DMUQNG6	Gastric cancer	2B72	Phase 1	[12]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TGN-1412	DMELNA8	Autoimmune diabetes	5A10	Discontinued in Phase 1	[13]

2 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anti-CD28	DM5BH7J	Immune System disease	4A01-4B41	Investigative	[14]
FR-104	DM7UP4E	Autoimmune diabetes	5A10	Investigative	[14]

References

• [1] New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT04590326) Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3). U.S.National Institutes of Health.
• [6] Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
• [7] ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
• [8] ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
• [9] Clinical pipeline report, company report or official report of Roche
• [10] Clinical pipeline report, company report or official report of Genentch
• [11] Clinical pipeline report, company report or official report of Sanofi.
• [12] Clinical pipeline report, company report or official report of Sanofi
• [13] TGN1412: From Discovery to Disaster. J Young Pharm. 2010 Jul-Sep; 2(3): 332-336.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2863).